PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization

PAREXEL International Corporation

today announced it is the first contract research organization (CRO) chosen by the Korea Drug Development Fund (KDDF) to help Korean companies develop and commercialize healthcare products for the global market. "Under the leadership of Dr. Dongho Lee, the KDDF is expected to be an important resource for emerging biopharmaceutical companies to advance their promising new technologies," said Ron Kraus, Corporate Vice President and Worldwide Head of PAREXEL Consulting and Medical Communications Services. "This partnership further demonstrates PAREXEL's continued commitment to the Asia-Pacific region and helps increase our opportunities for industry innovation. We are excited to provide our fusion of expertise to support KDDF and its mission of supporting global drug development."